HER2‐positive breast cancer brain metastasis: A new and exciting landscape

HER2‐positive breast cancer brain metastasis: A new and exciting landscape

Abstract Background Brain metastases (BrM) incidence is 25% to 50% in women with advanced human epidermal growth factor receptor 2 (HER2)‐positive breast cancer. Radiation and surgery are currently the main local treatment approaches for central nervous system (CNS) metastases. Systemic anti‐HER2 th...

Full description

Bibliographic Details
Main Authors: Alexandra S. Zimmer, Amanda E. D. Van Swearingen, Carey K. Anders
Format: Article
Language:English
Published: Wiley 2022-04-01
Series:Cancer Reports
Subjects:
brain metastasis
CNS involvement
HER2‐positive breast cancer
T‐DM1
trastuzumab
tucatinib
Online Access:https://doi.org/10.1002/cnr2.1274

Internet

https://doi.org/10.1002/cnr2.1274

Similar Items